<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6592">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959503</url>
  </required_header>
  <id_info>
    <org_study_id>NEO013-100</org_study_id>
    <nct_id>NCT01959503</nct_id>
  </id_info>
  <brief_title>Progel Vascular Sealant</brief_title>
  <official_title>A Prospective, Randomized Study to Compare Progel Vascular Sealant to Gelfoam Plus as an Adjunct for the Control of Bleeding in Subjects Undergoing Thoracic Aortic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the safety and effectiveness of the Progel
      Vascular Sealant for use in vascular reconstructions to achieve adjunctive hemostasis by
      mechanically sealing areas of leakage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this clinical study is to compare the time to hemostasis at the
      aortic anastomotic suture line in subjects receiving Progel (Test group) to that in subjects
      receiving Gelfoam Plus (Control group) on anastomotic suture lines involving the aortic
      valve, ascending aorta, or aortic arch while on cardiopulmonary bypass.

      The primary endpoint of this study is the time to achieve hemostasis at the aortic
      anastomotic suture line from the time surgical clamps are released to cessation of leakage
      at the treated anastomotic site with either Progel (Test) or Gelfoam Plus (Control).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to achieve hemostasis at the aortic anastomotic suture line from the time surgical clamps are released to cessation of leakage at the treated anastomotic site with either Progel or Gelfoam.</measure>
    <time_frame>Intra-procedurally</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve successful hemostasis at all treated aortic anastomotic suture lines following assigned treatment.</measure>
    <time_frame>5 minutes after application</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve immediate hemostasis, defined as 0 seconds, at all treated aortic anastomotic suture lines following assigned treatment.</measure>
    <time_frame>Intra-procedurally</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest tube drainage volume following surgery.</measure>
    <time_frame>24 hours post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total transfusion volume following surgery</measure>
    <time_frame>24 hours post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between cross clamp removal and request of surgical wires for sternal closure.</measure>
    <time_frame>Intra-procedurally</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of reoperations for aortic bleeding complications following treatment.</measure>
    <time_frame>30 days post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of device related serious adverse events per patient following assigned treatment.</measure>
    <time_frame>30 days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Aortic Valve While on Cardiopulmonary Bypass.</condition>
  <condition>Ascending Aorta While on Cardiopulmonary Bypass.</condition>
  <condition>Aortic Arch While on Cardiopulmonary Bypass.</condition>
  <arm_group>
    <arm_group_label>Progel Vascular Sealant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progel Vascular Sealant after confirmation of anastomotic leakage during intra-procedure leak test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelfoam Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gelfoam Plus Sealant after confirmation of anastomotic leakage during intra-procedure leak test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Progel Vascular Sealant</intervention_name>
    <arm_group_label>Progel Vascular Sealant</arm_group_label>
    <other_name>Progel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelfoam Plus</intervention_name>
    <arm_group_label>Gelfoam Plus</arm_group_label>
    <other_name>Gelfoam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Subject must be ≥ 18 years of age.

          -  2. Subject is scheduled for elective, primary thoracic surgery involving    the
             aortic valve, ascending aorta, or aortic arch on cardiopulmonary bypass.

          -  3. Subject has an expected life expectancy&gt; 6 months.

          -  4. Subject is willing and able to comply with all aspects of the study including
             follow-up schedule.

          -  5. Subject or authorized representative, has the ability to provide voluntary written
             informed consent.

        Intra-operative Inclusion Criteria:

          -  1. Subject is able to undergo an antegrade cardioplegia injection for evaluation of a
             leak at the aortic anastomotic site(s) during the procedure.

          -  2. Following this injection, subject has a leaking site where a topical
             sealant/hemostatic agent may be used to control bleeding.

        Exclusion Criteria:

          -  1. Subject has Type A or other acute thoracic aortic dissection.

          -  2. Subject has undergone prior thoracic surgery (open thoracotomy not including
             interventional cardiology procedures).

          -  3. Subject is undergoing a planned concomitant procedure other than coronary artery
             bypass graft (CABG).

          -  4. Subject has a previous organ transplant.

          -  5. Subject has known or suspected preoperative coagulation disorder.

          -  6. Subject is allergic to human thrombin or has a history of allergic reactions after
             application of human thrombin.

          -  7. Subject is allergic to protamine.

          -  8. Subject has a Left Ventricular Assist Device (LVAD) or planned to receive an LVAD.

          -  9. Subject is undergoing emergency surgery.

          -  10. Subject is in chronic renal failure.

          -  11. Subject has a hematocrit &lt; 21% pre-operatively.

          -  12. Subject has a serum creatinine ≥2.5 mg/dl at baseline or is currently on
             dialysis.

          -  13. Subject has a cardiac ejection fraction &lt;25%.

          -  14. Subject is scheduled for another cardiac surgery within 30 days of enrollment.

          -  15. Subject has an active or latent infection which is systemic or at the intended
             surgery site.

          -  16. Subject is immuno-compromised such as that resulting from chronic oral steroid
             use, chemotherapeutic agents, or immune deficiency disorders.

          -  17. Subject is pregnant by a positive pregnancy test or has plans to become pregnant
             during the study period or is currently breast-feeding.

          -  18. Subject is unwilling to receive blood products.

          -  19. Subject has participated in another investigational research study within 30 days
             of enrollment.

          -  20. In the opinion of the investigator, the subject has a clinical condition that
             would preclude the use of the study device, preclude the subject from completing the
             follow-up requirements, or would complicate the evaluation of this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Khoynezhad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Melloy</last_name>
    <phone>908-277-8094</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Davies, MD</last_name>
    </contact>
    <investigator>
      <last_name>James Davies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Khoynezhad, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ali Khoynezhad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brett Reece, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brett Reece, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomas Martin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tomas Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Portneuf Hospital</name>
      <address>
        <city>Pocatello</city>
        <state>Idaho</state>
        <zip>83201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob DeLaRosa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jacob DeLaRosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Malaisrie, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christopher Malaisrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Himanshu Patel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Himanshu Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Pochettino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Pochettino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Moon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc Moon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryan Heart</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Thompson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Michler</last_name>
    </contact>
    <investigator>
      <last_name>Robert Michler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonard Girardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leonard Girardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Spielvogel, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Spielvogel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Health Care System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Skipper</last_name>
    </contact>
    <investigator>
      <last_name>Eric Skipper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jefferson Lyons</last_name>
    </contact>
    <investigator>
      <last_name>Jefferson Lyons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nimesh Desai, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nimesh Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Brinkman, MD</last_name>
    </contact>
    <investigator>
      <last_name>William Brinkman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Doty</last_name>
    </contact>
    <investigator>
      <last_name>John Doty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aorta</keyword>
  <keyword>Aortic</keyword>
  <keyword>Reconstruction</keyword>
  <keyword>CABG</keyword>
  <keyword>Bypass</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gelatin Sponge, Absorbable</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
